Does This Biotech Have the Secret to Conquering Covid Variants?
Gritstone Bio (NASDAQ: GRTS) is far from being the first to the coronavirus vaccine finish line. The biotech company's vaccine candidate just began phase 1 trials this year. Like vaccine leaders Pfizer and Moderna, Gritstone's candidate uses mRNA technology. Wait a minute, you might say. Aren't those highly successful vaccines? Why do we need another?
And is there room for a latecomer? Gritstone's clinical trials are in the earliest stage. Even if all goes smoothly, a potential product probably wouldn't be ready until the pandemic is over. But this one may be worth waiting for. Let's take a closer look at why you should keep an eye on this small but exciting player.
Source Fool.com